<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04607252</url>
  </required_header>
  <id_info>
    <org_study_id>V01 2020-10</org_study_id>
    <nct_id>NCT04607252</nct_id>
  </id_info>
  <brief_title>Metformin Plus Megestrol Acetate as a Fertility-sparing Treatment in Patients With Atypical Endometrial Hyperplasia</brief_title>
  <official_title>Comparing Metformin Plus Megestrol Acetate With Megestrol Acetate Alone as a Fertility-sparing Treatment in Patients With Atypical Endometrial Hyperplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To verify whether metformin could improve the effect of progestin as fertility-sparing&#xD;
      treatment in patients with atypical endometrial hyperplasia(AEH).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Whether metformin could improve the effect of progestin as fertility-sparing treatment in&#xD;
      patients with atypical endometrial hyperplasia(AEH) is still not clear. Our previous finding&#xD;
      from subgroup analysis in a phase II randomized controlled trial showed that 39.6% of AEH&#xD;
      patients in metformin plus megestrol acetate group achieved complete response, compared with&#xD;
      20.4% in group of megestrol acetate alone. This trial aim to fully testify the effect of&#xD;
      metformin in fertility-sparing treatment for AEH patients with adequate sample size.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 11, 2021</start_date>
  <completion_date type="Anticipated">February 28, 2027</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2024</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete response within 16 weeks of treatment</measure>
    <time_frame>16 weeks</time_frame>
    <description>reversion of AEH The reversion of AEH to proliferative or secretory endometrium</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete response within 32 weeks of treatment</measure>
    <time_frame>32 weeks</time_frame>
    <description>The reversion of AEH to proliferative or secretory endometrium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>32 weeks</time_frame>
    <description>Adverse events during the treatment of metformin plus megestrol acetate or megestrol acetate alone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2-year recurrence rate</measure>
    <time_frame>2 years</time_frame>
    <description>recurrence rate within 2 years after the treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2-year pregnancy rate</measure>
    <time_frame>2 years</time_frame>
    <description>Pregnancy rate within 2 years after the treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2-year live-birth rate</measure>
    <time_frame>2 years</time_frame>
    <description>Live-birth rate within 2 years after the treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">192</enrollment>
  <condition>Atypical Endometrial Hyperplasia</condition>
  <arm_group>
    <arm_group_label>Metformin plus megestrol acetate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin 1500mg per day plus megestrol acetate 160mg per day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Megestrol acetate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Megestrol acetate 160mg per day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin plus Megestrol acetate</intervention_name>
    <description>metformin 1500mg, per day, oral; megestrol acetate 160mg per day, oral</description>
    <arm_group_label>Metformin plus megestrol acetate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Megestrol Acetate</intervention_name>
    <description>megestrol acetate 160mg per day, oral</description>
    <arm_group_label>Megestrol acetate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18-45 years old;&#xD;
&#xD;
          2. pathologically diagnosed with AEH for the first time;&#xD;
&#xD;
          3. desire to preserve their fertility;&#xD;
&#xD;
          4. no signs of suspicious myometrial invasion or extrauterine metastasis by enhanced&#xD;
             magnetic resonance imaging (MRI), enhanced computed tomography (CT) or transvaginal&#xD;
             ultrasonography (TVUS);&#xD;
&#xD;
          5. no contraindication for metformin, megestrol acetate or pregnancy;&#xD;
&#xD;
          6. no hormone or metformin treatment within 6 months before entering the trial;&#xD;
&#xD;
          7. not pregnant when participating in the trial;&#xD;
&#xD;
          8. willing to follow the trial arrangement after being fully informed of all the risks&#xD;
             and inconveniences caused by the trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients who had one or more of the following conditions:&#xD;
&#xD;
          1. allergy history or contraindications for megestrol acetate or metformin;&#xD;
&#xD;
          2. pregnant when initiating the study;&#xD;
&#xD;
          3. alcoholism, severe infection, severe chronical diseases (dysfunction of heart, liver,&#xD;
             lung or kidney);&#xD;
&#xD;
          4. high risk of thrombosis;&#xD;
&#xD;
          5. recurrent AEH;&#xD;
&#xD;
          6. endometrial cancer;&#xD;
&#xD;
          7. other malignancy history.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaojun Chen, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Obstetrics &amp; Gynecology Hospital of Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jun Guan, MD</last_name>
    <phone>008615618262406</phone>
    <email>junguan2018@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Obstetrics and Gynecology Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Guan, MD</last_name>
      <phone>008615618262406</phone>
      <email>junguan2018@163.com</email>
    </contact>
    <contact_backup>
      <email>xiaomihaoku@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Xiaojun Chen, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 23, 2020</study_first_submitted>
  <study_first_submitted_qc>October 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2020</study_first_posted>
  <last_update_submitted>February 6, 2021</last_update_submitted>
  <last_update_submitted_qc>February 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Xiaojun Chen</investigator_full_name>
    <investigator_title>Prof.Dr</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Hyperplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Megestrol</mesh_term>
    <mesh_term>Megestrol Acetate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Data will be shared with other researchers without patients' personal information after all the findings being published.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

